September 4, 2012
AlloCure Begins Phase 2 Clinical Trial in Acute Kidney Injury
200-Subject Trial of Novel Cell Therapy AC607 at leading tertiary care centers in the United States
Press release
April 2, 2012
AlloCure Raises $25 Million Series B Venture Financing
New Funding to Support Phase 2 Trial of Novel Therapy for Acute Kidney Injury
Press release
January 5, 2012
AlloCure's Investigational Treatment for Acute Kidney Injury Receives Fast Track Designation by FDA
Press release
November 14, 2011
AlloCure Presents Safety and Preliminary Efficacy of AC607 for the Treatment of Acute Kidney Injury at ASN
Phase 1 Trial Results Presented at "Kidney Week 2011"
Press release
July 6, 2010
AlloCure Names Robert M. Brenner, M.D. Chief Executive Officer
Press release
© 2014 AlloCure.